Doctor Thomas Frye currently serves as Associate Professor of Urology and Vice Chair of Clinical Affairs for the Department of Urology at the University of Rochester Medical Center. Dr. Frye, is a Urologic Oncologist who specializes in both minimally invasive urologic oncology (robotic surgery of prostate and kidney cancers), and advanced open pelvic and retroperitoneal cancer surgery. He has a special interest and expertise in the management of localized prostate cancer with focal therapy. Dr. Frye has the most comprehensive focal therapy program in upstate New York and offers High Intensity Focused Ultrasound (HIFU), cryotherapy, as well as other ablative technologies. He also participates in national clinical trials evaluating the efficacy of focal therapy for prostate cancer.

Dr. Frye was the valedictorian of his class where he graduated with a Doctor of Osteopathy degree from Midwestern University, Chicago College of Osteopathic Medicine. He went on to complete his urology residency at Southern Illinois University School of Medicine. Dr. Frye was chosen for the prestigious fellowship training in Urologic Oncology within The National Cancer Institute at the National Institutes of Health (NIH) in Bethesda, Maryland.

Dr. Frye’s research projects focus on optimizing the screening, diagnosis and treatment of men with prostate cancer. During his fellowship, he worked extensively in refining the use of prostate MRIs in men on active surveillance. Dr. Frye's clinical research interest also includes advanced imaging for prostate cancer as well as focal therapy of prostate cancer.

Dr. Frye is involved in multiple specialty societies including the American Urological Association (AUA), Society of Urologic Oncology (SUO), American Society of Clinical Oncology, and Focal Therapy Society.

Certified Specialties

Urology - American Board of Urology

Faculty Appointments

Associate Professor - Department of Urology (SMD)

Credentials

Residency & Fellowship

Fellowship, Urologic Oncology, National Cancer Institute/National Institute of Health. 2014 - 2016

Residency, Urology, Southern Illinois University School Of Medicine. 2010 - 2014

Internship, Urology, Southern Illinois University School Of Medicine. 2009 - 2010

Education

DO | Midwestern University. 2009

Research

Clinical Trials

Phase III Trial of Immunotherapy-Based Combination Therapy With or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)

Lead Researcher: Thomas P Frye

This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with kidney cancer that has spread to othe...

Prospective, Multicenter, Single-Arm Study of VanquishTM Water Vapor Ablation for PrOstate CanceR

Lead Researcher: Thomas P Frye

The purpose of this study is to evaluate the safety and efficacy of the Vanquish Water Vapor Ablation Device ("Vanquish") in treating subjects with Gleason Grade Group 2 (GGG2) localized intermediate-risk prostate cancer.

Publications

Journal Articles

Multi-institutional validation of a Perfused Robot-Assisted Partial Nephrectomy Procedural Simulation platform utilizing clinically relevant objective metrics of simulators (CROMS).

Ghazi A, Melnyk R, Hung AJ, Collins J, Ertefaie A, Saba P, Gurung P, Frye T, Rashid H, Wu G, Mottrie A, Costello T, Dasgupta P, Joseph J

BJU international.. 2020 September 16 Epub 09/16/2020.

Robot-assisted Synchronous Bilateral Nephrectomy for Autosomal Dominant Polycystic Kidney Disease: a Stepwise Description of Technique.

Gurung PMS, Frye TP, Rashid HH, Joseph JV, Wu G

Urology.. 2020 June 17 Epub 06/17/2020.

Incorporation and validation of clinically relevant performance metrics of simulation (CRPMS) into a novel full-immersion simulation platform for nerve-sparing robot-assisted radical prostatectomy (NS-RARP) utilizing three-dimensional printing and hydrogel casting technology.

Witthaus MW, Farooq S, Melnyk R, Campbell T, Saba P, Mathews E, Ezzat B, Ertefaie A, Frye TP, Wu G, Rashid H, Joseph JV, Ghazi A.

BJU Int. 2020; .

Cribriform pattern and perineural invasion on MR/US fusion biopsy predict failure of selection criteria for prostatic hemigland ablation

Mithal P, Truong M, Quarrier S, Lu D, Hollenberg G, Weinberg E, Miyamoto H, Frye T.

Urol Oncol. 2020; .

Multi-institutional Clinical Tool for Predicting High-risk Lesions on 3Tesla Multiparametric Prostate Magnetic Resonance Imaging

Truong M, Baack Kukreja JE, Rais-Bahrami S, Barashi NS, Wang B, Nuffer Z, Park JH, Lam K, Frye TP, Nix JW, Thomas JV, Feng C, Chapin BF, Davis JW, Hollenberg G, Oto A, Eggener SE, Joseph JV, Weinberg E, Messing EM.

Eur Urol Oncol. 2019; .

Sonographic Diagnosis of Unilateral Synchronous Testicular Tumors

Forrest A, Numbere N, Jean-Gilles J, Frye T, Dogra V.

Am J Sonogr. 2019; .

A Festschrift in Honor of Edward M. Messing, MD, FACS.

Joseph JV, Brasacchio R, Fung C, Reeder J, Bylund K, Sahasrabudhe D, Yeh SY, Ghazi A, Fultz P, Rubens D, Wu G, Singer E, Schwarz E, Mohile S, Mohler J, Theodorescu D, Lee YF, Okunieff P, McConkey D, Rashid H, Chang C, Fradet Y, Guru K, Kukreja J, Sufrin G, Lotan Y, Bailey H, Noyes K, Schwartz S, Rideout K, Bratslavsky G, Campbell SC, Derweesh I, Abrahamsson PA, Soloway M, Gomella L, Golijanin D, Svatek R, Frye T, Lerner S, Palapattu G, Wilding G, Droller M, Trump D

Bladder cancer.. 2018 October 34 (Suppl 1):S1-S43. Epub 10/03/2018.

A Comprehensive Analysis of Cribriform Morphology on MR/US Fusion Biopsy Correlated with Radical Prostatectomy Specimens.

Truong M, Feng C, Hollenberg G, Weinberg E, Messing EM, Miyamoto H, Frye TP.

Journal of Urology. 2018; .

Historical and contemporary perspectives on cribriform morphology in prostate cancer.

Truong M, Frye T, Messing E, Miyamoto H.

Nat Rev Urol. 2018; .

Magnetic resonance imaging detection of prostate cancer in men with previous negative prostate biopsy.

Truong M;Frye TP.

Transl Androl Urol. 2017; 6(3): 424-431.

MRI-TRUS Guided Fusion Biopsy to Detect Progression in Patients with Existing Lesions on Active Surveillance for Low and Intermediate Risk Prostate Cancer

Frye TP, George A, Kilchevsky A, Maruf M, Siddiqui M, Kongnyuy M, Muthigi A, Han H, Parnes H, Merino M, Choyke P, Turkbey B, Wood B, Pinto P.

Journal of Urology. 2017; .

Impact of Gleason Subtype on Prostate Cancer Detection Using Multiparametric MRI: Correlation with Final Histopathology

Truong M, Hollenberg G, Weinberg E, Messing EM, Miyamoto H, Frye TP.

Journal of Urology. 2017; .

The prostate cancer prevention trial risk calculator 2.0 performs equally for standard biopsy and MRI/US fusion-guided biopsy

Maruf M, Fascelli M, George AK, Siddiqui MM, Kongnyuy M, DiBianco JM, Muthigi A, Valayil S, Sidana A, Frye TP, Kilchevsky A, Choyke PL, Turkbey B, Wood BJ, Pinto PA.

Prostate Cancer Prostatic Dis. 2017; .

Prostate Cancer Diagnosis on repeat MRI-TRUS Fusion Biopsy of Benign Lesions: Recommendations for Repeat Sampling

Chelluri R, Kilchevsky A, George AK, Sidana A, Frye TP, Su D, Fascelli M, Ho R, Abboud SF, Turkbey B, Merino MJ, Choyke PL, Wood BJ, Pinto PA.

J Urol. 2016; : pii: S0022-5347(16)00327-X. doi: 10.1016.

Reproducibility of Multiparametric MRI and Fusion-Guided Prostate Biopsy: Multi-Institutional External Validation by a Propensity Score Matched Cohort

Rastinehad AR, Abboud SF, George AK, Frye T, Ho R, Chelluri R, Fascelli M, Shih J, Villani R, Ben-Levi E, Yaskiv O, Turkbey B, Choyke PL, Merino MJ, Wood BJ, Pinto PA.

J Urol. 2016; pii: S0022-5347(16)00129-4.

Reproducibility of Multiparametric Magnetic Resonance Imaging and Fusion Guided Prostate Biopsy: Multi-Institutional External Validation by a Propensity Score Matched Cohort.

Rastinehad AR, Abboud SF, George AK, Frye T, Ho R, Chelluri R, Fascelli M, Shih J, Villani R, Ben-Levi E, Yaskiv O, Turkbey B, Choyke PL, Merino MJ, Wood BJ, Pinto PA.

Journal of Urology. 2016; .

The significance of anterior prostate lesions on multiparametric magnetic resonance imaging in African-American men

Kongnyuy M, Sidana A, George AK, Muthigi A, Iyer A, Fascelli M, Kadakia M, Frye TP, Ho R, Mertan F, Minhaj Siddiqui M, Su D, Merino MJ, Turkbey B, Choyke PL, Wood BJ, Pinto PA.

Urol Oncol. 2016; .

Midline lesions of the prostate: role of MRI/TRUS fusion biopsy and implications in Gleason risk stratification.

18. Muthigi A, Sidana A, George AK, Kongnyuy M, Shakir N, Kadakia M, Maruf M, Frye TP, Mertan F, Su D, Merino MJ, Choyke PL, Turkbey B, Wood BJ, Pinto PA.

Int Urol Nephrol. 2016; .

Preoperative Multiparametric Magnetic Resonance Imaging Predicts Biochemical Recurrence in Prostate Cancer after Radical Prostatectomy

Ho R, Siddiqui MM, George AK, Frye T, Kilchevsky A, Fascelli M, Shakir NA, Chelluri R, Abboud SF, Walton-Diaz A, Sankineni S, Merino MJ, Turkbey B, Choyke PL, Wood BJ, Pinto PA.

PLoS One. 2016; .

Midline lesions of the prostate: role of MRI/TRUS fusion biopsy and implications in Gleason risk stratification

Muthigi A, Sidana A, George AK, Kongnyuy M, Shakir N, Kadakia M, Maruf M, Frye TP, Mertan F, Su D, Merino MJ, Choyke PL, Turkbey B, Wood BJ, Pinto PA.

Int Urol Nephrol. 2016; .

Risk stratification of prostate cancer: integrating multiparametric MRI, nomograms and biomarkers

Watson MJ, George AK, Maruf M, Frye TP, Muthigi A, Kongnyuy M, Valayil SG, Pinto PA.

Future Oncol. 2016; .

Tumor contact with prostate capsule on magnetic resonance imaging: A potential biomarker for staging and prognosis

Kongnyuy M, Sidana A, George AK, Muthigi A, Iyer A, Ho R, Chelluri R, Mertan F, Frye TP, Su D, Merino MJ, Choyke PL, Wood BJ, Pinto PA, Turkbey B.

Urol Oncol. 2016; .

A Case of In-Bore Transperineal MRI-Guided Prostate Biopsy of a Patient with Ileal Pouch-Anal Anastomosis

Kongnyuy M, Frye TP, George AK, et al.

Case Reports in Urology. 2015; .

Combined Biparametric Prostate MRI and Prostate Specific Antigen in the Detection of Prostate Cancer: a Validation Study in a Biopsy Naïve Patient Population

Fascelli M, Rais-Bahrami S, Sankineni S, Brown AM, George AK, Ho R, Frye T, Kilchevsky A, Chelluri R, Abboud S, Siddiqui MM, Merino MJ, Wood BJ, Choyke PL, Pinto PA, Turkbey B.

Urology. 2015; pii: S0090-4295(15)01091-2.

Optimizing Patient Population for MP-MRI and Fusion Biopsy for Prostate Cancer Detection

Frye TP, Pinto PA, George AK.

Curr Urol Rep. 2015; 16(7):50.

The role of MRI in active surveillance for prostate cancer

Fascelli M, George AK, Frye T, Turkbey B, Choyke PL, Pinto PA.

Curr Urol Rep. 2015; 16(6):42.

Impact of County Rurality and Urologist Density on Urologic Cancer Mortality in Illinois

Frye TP, Sadowski DJ, Zahnd WE, Jenkins WD, Dynda DI, Mueller GS, Alanee SR, McVary KT.

J Urol. 2015; 193(5):1608-13.

Conservative management and female gender are associated with increased cancer?specific death in patients with isolated primary urothelial carcinoma in situ.

Alanee S, Bauman J, Dynda D, Frye T, Konety B, Schwartz B.

Eur J Cancer Care (Engl). 2014; .

Robot-Assisted Inguinal Lymphadenectomy for Urethral Carcinoma

Frye TP, Gorbonos A.

J Laparoendoscopic & Advanced Surgical Techniques and Part B: Videoscopy. 2014; .

Ocular Radiation Exposure in Modern Urologic Practice

Taylor ER, Kramer B, Frye TP, Wang S, Schwartz BF, Köhler TSJ.

Urol. 2013; .

Immunization with a prostate cancer xenoantigen elicits a xenoantigen epitope-specific T-cell response

Johnson LE, Frye TP, McNeel DG.

OncoImmunology. 2012; 1;1(9):1546-1556.

Patient Satisfaction of Vacuum Erection Device (VED) Use After Prostate Cancer Treatment: Three and Six Month Outcomes from a VED Registry

Kohler TS, Frye TP, Rewcastle JC, Mulhall JP.

J Sex. Med. 2012; 9:219.

HLA-A2 restricted T-cell epitopes specific for prostatic acid phosphatase

Olson BM, Frye TP, Johnson LE, Fong L, Knutson KL, Disis ML, McNeel DG . 2010 Jun;.

Cancer Immunol Immunother. 2010; 59(6):943-53.

Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer

McNeel DG, Dunphy EJ, Davies JG, Frye TP, Johnson LE, Staab MJ, Horvath DL, Straus J, Alberti D, Marnocha R, Liu G, Eickhoff JC, Wilding G.

J Clin Oncol. 2009; 27:4047-4054.

Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T-cells

Johnson LE, Frye TP, Chinnasamy N, Chinnasamy G, and McNeel DG.

Cancer Immunol Immunother. 2007; 56(6):885-95.

Safety and immunological efficacy of prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP)

Johnson LE, Frye TP, Arnot AR, Marquette C, Couture LA, Gendron-Fitzpatrick A, and McNeel DGVaccine.

2006; 24:293-303.

New approaches to identification of antigenic candidates for future prostate cancer immunotherapy

Dunphy EJ, Johnson LE, Olson BM, Frye TP, McNeel DG.

Update on Cancer Therapeutics. 2006; 22:273-284.

Books

Neuropsychology of Cancer and Oncology (2012)

Chapter: Neuropsychology of Genitourinary Malignancies

Authors: Frye TP, Miller J, Tarter TH

Publisher: Springer Publishing Company 2012

Ratings & Reviews

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.